日本語 
I see that the global market for chronic kidney disease drugs is growing fast. Sales across seven pharmaceutical markets are expected to rise from $4.3 billion in 2025 to $10.9 billion in 2035. This forecast, cited by Healthcare Asia Magazine from GlobalData shows a compound growth rate of 9.8%. The United States will remain the market but this outlook also matters for Japans pharmaceutical and healthcare technology industries.
I think this chance is especially important for Japan because Japan will have the diagnosed CKD cases among the seven large markets by 2035. GlobalData predicts that about 5.85 million Japanese people will have diagnosed CKD in 2035.
I feel that this mix of an aging population, strong healthcare demand and new treatments for CKD could turn CKD into a focus for pharmaceutical innovation and HealthTech investment.
I know that CKD creates a growing challenge for health care. CKD often grows slowly. Can be unnoticed until kidney function has already dropped a lot. Diabetes, high blood pressure and heart disease are factors linked to CKD making care difficult because patients may need long‑term monitoring and many treatments.
I notice that the growth looks small but CKD will have a long‑term impact. The GlobalData forecast says diagnosed CKD prevalence in the seven markets will rise at a rate of 0.83% until 2035 and CKD needs continuous care and can move to worse stages of kidney failure.
I understand that for health care systems, like Japans the challenge is not to create new medicines. The challenge is also to spot patients and to make sure CKD treatment can be given well over a long time.
Japan is a place in the future plan. The number of people in Japan who have CKD is expected to be 5.9 million by the year 2035. Because of this drug makers have a reason to create medicines and new tools that fit Japanese patients.
The Japanese drug industry can grow from this need. It can do research into ways to work inside the body try medicines that are used together and make treatments that slow down the worsening of CKD.
Also the market can bring teamwork between drug makers, hospitals, universities and new technology companies. These teams can speed up the making of tools that use data and AI analysis to find people who are at higher risk of CKD getting worse.
AI Could Improve CKD Detection and Management
The chance with CKD is not about making new medicines. AI and data analysis can also become very important in how we look after kidney disease.
Doctors and nurses already get a lot of data from blood tests, pictures of the body, electronic records and everyday checks. AI systems can help doctors see patterns that show kidney health is dropping and help them act earlier.
For technology companies this gives chances to build prediction tools, support tools for doctors and systems that check patients from far away.
The rise of research that uses machine learning to predict CKD risk shows how big the chance is. Recent studies have used health data from people and machine learning to find what makes CKD happen and to make better risk lists.
The chance, with money will depend on how these tools can fit into the everyday work of doctors and keep data safe, correct and following rules.
Pharmaceutical Competition Will Intensify
The projected growth of the market will also bring competition. GlobalData highlights a challenge: many established products are nearing or losing exclusivity. Drugs such as Forxiga (dapagliflozin) Jardiance (empagliflozin) and Kerendia (finerenone) are expected to see sales decline as generic competitors appear.
This creates a cycle in the pharmaceutical industry. When older products lose exclusivity companies must develop therapies to replace falling revenue. The outcome may be investment in new CKD mechanisms, clinical trials and targeted treatments.
For pharmaceutical businesses this situation offers both an opportunity and a challenge. Companies that offer therapies could capture new demand but they must show meaningful clinical benefits in an increasingly competitive market.
HealthTech Businesses Could Gain From Diagnosis
The biggest long‑term benefit could come from combining treatment with earlier detection.
Technology companies that develop kidney‑health monitoring tools could help hospitals spot deterioration before patients reach stages of disease. Digital health platforms could also help patients stick to medication manage lifestyle and keep in touch with clinicians.
This could create opportunities across Japans HealthTech ecosystem, such as AI, medical devices, cloud computing, cybersecurity, remote monitoring and healthcare data platforms.
The expansion of Japans dialysis market also shows the economic impact of kidney disease. One recent forecast estimates that Japans dialysis products and services market could grow from $5.8 billion in 2025 to $11.19 billion by 2035.
What It Means for Businesses in Japan
The projected growth of the CKD drug market signals a shift in healthcare technology. Pharmaceutical companies will stay central. Future growth will likely depend on ecosystems that bring together drugs, diagnostics, data and digital services.
Japanese businesses that can link these areas may have an advantage. For example a pharmaceutical company that develops a CKD therapy could partner with an AI provider to spot suitable patients with a diagnostics company to improve monitoring and with a cloud platform to safely manage clinical data.
Also Read: GlycanAge and ExoEarth Partnership Could Accelerate Japan’s Longevity Tech Market
For investors and technology companies CKD is more than a pharmaceutical market opportunity. It is becoming a healthcare opportunity.
As CKD prevalence rises and healthcare systems feel pressure to manage diseases more efficiently Japan could see more investment in kidney‑focused drug development, AI‑assisted diagnosis, remote monitoring and personalized treatment.
The projected $10.9 billion CKD drug market by 2035 is a signal, for Japans healthcare industry. It points to a future where pharmaceutical innovation and HealthTech work together closely to detect kidney disease earlier slow its progression and lessen the long‑term burden on patients and healthcare providers.
English